PURSUIT risk score: Difference between revisions
Jump to navigation
Jump to search
(Created page with "The PURSUIT (Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy) risk score was developed in a randomized clinical trial which re...") |
No edit summary |
||
| Line 1: | Line 1: | ||
The PURSUIT (Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy) risk score was developed in a randomized clinical trial which recruited 9,461 patients and compared eptifibatide (Integrilin) to placebo in the management of Unstable Angina (UA) or Non-ST elevation Myocardial Infarction (NSTEMI) | === Definition and History === | ||
The PURSUIT (Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy) risk score was developed in a randomized clinical trial which recruited 9,461 patients and compared eptifibatide (Integrilin) to placebo in the management of Unstable Angina (UA) or Non-ST elevation Myocardial Infarction (NSTEMI). | |||
=== Function === | |||
<br /> | |||
Revision as of 22:11, 11 February 2020
Definition and History
The PURSUIT (Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy) risk score was developed in a randomized clinical trial which recruited 9,461 patients and compared eptifibatide (Integrilin) to placebo in the management of Unstable Angina (UA) or Non-ST elevation Myocardial Infarction (NSTEMI).
Function